Currax Pharmaceuticals: CONTRAVE(R)/MYSIMBA(R) demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

Currax Pharmaceuticals LLC(Currax) today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE(R)/MYSIMBA(R), a weight management drug. The real-world study

Related Keywords

Michael Kyle ,George Hampton ,Cardiovascular Health Outcomes Analysis ,Drug Administration ,Currax Pharmaceuticals ,European Medicines Agency ,Health Outcomes Analysis ,European Union ,Chief Medical ,Currax President ,Health Outcomes ,European Economic Area ,